Tight regulation between cell survival and programmed cell death in GBM stem-like cells by EGFR/GSK3b/PP2A signaling
- 943 Downloads
Malignant gliomas represent one of the most aggressive forms of cancer, displaying high mortality rates and limited treatment options. Specific subpopulations of cells residing in the tumor niche with stem-like characteristics have been postulated to initiate and maintain neoplasticity while resisting conventional therapies. The study presented here aims to define the role of glycogen synthase kinase 3 beta (GSK3b) in patient-derived glioblastoma (GBM) stem-like cell (GSC) proliferation, apoptosis and invasion. To evaluate the potential role of GSK3b in GBM, protein profiles from 68 GBM patients and 20 normal brain samples were analyzed for EGFR-mediated PI3kinase/Akt and GSK3b signaling molecules including protein phosphatase 2A (PP2A). To better understand the function of GSK3b in GBM, GSCs were isolated from GBM patient samples. Blocking GSK3b phosphorylation at Serine 9 attenuated cell proliferation while concomitantly stimulating apoptosis through activation of Caspase-3 in patient-derived GSCs. Increasing GSK3b protein content resulted in the inhibition of cell proliferation, colony formation and stimulated programmed cell death. Depleting GSK3b in GSCs down regulated PP2A. Furthermore, knocking down PP2A or blocking its activity by okadaic acid inactivated GSK3b by increasing GSK3b phosphorylation at Serine 9. Our data suggests that GSK3b may function as a regulator of apoptosis and tumorigenesis in GSCs. Therapeutic approaches targeting GSK3b in glioblastoma stem-like cells may be a useful addition to our current therapeutic armamentarium.
KeywordsGlioblastoma Cancer stem cells EGFR Glycogen synthase kinase 3 PP2A Apoptosis
The authors would like to thank Maria Irina Chiriac for excellent technical assistance in preparing the figures of this manuscript.
The authors declare that they have no conflict of interest. The authors report no financial or material support concerning the materials or methods used in this study or the findings specified in this paper.
- 1.Bleau AM, Howard BM, Taylor LA, Gursel D, Greenfield JP, Lim Tung HY, Holland EC, Boockvar JA (2008) New strategy for the analysis of phenotypic marker antigens in brain tumor-derived neurospheres in mice and humans. Neurosurg Focus 24:E28. doi: 10.3171/FOC/2008/24/3-4/E27 PubMedCrossRefGoogle Scholar
- 2.Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, Bayani J, Head R, Lee M, Bernstein M, Squire JA, Smith A, Dirks P (2009) Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4:568–580. doi: 10.1016/j.stem.2009.03.014 PubMedCrossRefGoogle Scholar
- 7.Ring DB, Johnson KW, Henriksen EJ, Nuss JM, Goff D, Kinnick TR, Ma ST, Reeder JW, Samuels I, Slabiak T, Wagman AS, Hammond ME, Harrison SD (2003) Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 52:588–595PubMedCrossRefGoogle Scholar
- 8.Ougolkov AV, Fernandez-Zapico ME, Bilim VN, Smyrk TC, Chari ST, Billadeau DD (2006) Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clinical cancer research : an official journal of the American Association for Cancer Research 12:5074–5081. doi: 10.1158/1078-0432.CCR-06-0196 CrossRefGoogle Scholar
- 10.Kang T, Wei Y, Honaker Y, Yamaguchi H, Appella E, Hung MC, Piwnica-Worms H (2008) GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 13:36–47. doi: 10.1016/j.ccr.2007.12.002 PubMedCentralPubMedCrossRefGoogle Scholar
- 11.Ding Q, Xia W, Liu JC, Yang JY, Lee DF, Xia J, Bartholomeusz G, Li Y, Pan Y, Li Z, Bargou RC, Qin J, Lai CC, Tsai FJ, Tsai CH, Hung MC (2005) Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 19:159–170. doi: 10.1016/j.molcel.2005.06.009 PubMedCrossRefGoogle Scholar
- 14.Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD (2005) Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 65:2076–2081. doi: 10.1158/0008-5472.CAN-04-3642 PubMedCrossRefGoogle Scholar
- 15.Tan J, Zhuang L, Leong HS, Iyer NG, Liu ET, Yu Q (2005) Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res 65:9012–9020. doi: 10.1158/0008-5472.CAN-05-1226 PubMedCrossRefGoogle Scholar
- 20.Gursel DB, Beyene RT, Hofstetter C, Greenfield JP, Souweidane MM, Kaplitt M, Arango-Lievano M, Howard B, Boockvar JA (2011) Optimization of glioblastoma multiforme stem cell isolation, transfection, and transduction. J Neurooncol 104:509–522. doi: 10.1007/s11060-011-0528-2 PubMedCrossRefGoogle Scholar
- 22.Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, Muzikansky A, Loeffler JS (2004) The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22:1926–1933. doi: 10.1200/JCO.2004.07.193 CrossRefGoogle Scholar
- 24.Miyashita K, Kawakami K, Nakada M, Mai W, Shakoori A, Fujisawa H, Hayashi Y, Hamada J, Minamoto T (2009) Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research 15:887–897. doi: 10.1158/1078-0432.CCR-08-0760 CrossRefGoogle Scholar
- 26.Cross DA, Alessi DR, Vandenheede JR, McDowell HE, Hundal HS, Cohen P (1994) The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf. Biochem J 303(Pt 1):21–26PubMedCentralPubMedGoogle Scholar
- 32.Stegh AH, Kesari S, Mahoney JE, Jenq HT, Forloney KL, Protopopov A, Louis DN, Chin L, DePinho RA (2008) Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci USA 105:10703–10708. doi: 10.1073/pnas.0712034105 PubMedCentralPubMedCrossRefGoogle Scholar
- 40.Lu J, Kovach JS, Johnson F, Chiang J, Hodes R, Lonser R, Zhuang Z (2009) Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc Natl Acad Sci USA 106:11697–11702. doi: 10.1073/pnas.0905930106 PubMedCentralPubMedCrossRefGoogle Scholar
- 41.Hofstetter CP, Burkhardt JK, Shin BJ, Gursel DB, Mubita L, Gorrepati R, Brennan C, Holland EC, Boockvar JA (2012) Protein phosphatase 2A mediates dormancy of glioblastoma multiforme-derived tumor stem-like cells during hypoxia. PLoS One 7:e30059. doi: 10.1371/journal.pone.0030059 PubMedCentralPubMedCrossRefGoogle Scholar
- 42.Kuo YC, Huang KY, Yang CH, Yang YS, Lee WY, Chiang CW (2008) Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem 283:1882–1892. doi: 10.1074/jbc.M709585200 PubMedCrossRefGoogle Scholar